12:00 AM
 | 
Feb 07, 2005
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 4Q04EPS est 4Q04 EPS actual Outcome Growth from 4Q03 2/4 cls Wk chg % chg Mcap chg 2/4 mcap
Alkermes (A) -$0.13 -$0.10 Beat by $0.03 NA $12.60 $0.13 1% $11.7 $1,136.2
Revenues from partner Johnson & Johnson's sales of Risperdal Consta were $16.6M. For its 4Q05, ALKS reduced its R&D revenue guidance to $25-$30M from $40-$60M, after removing expected revenues...

Read the full 420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >